Security Snapshot

Kronos Bio, Inc. - Common Stock (KRON) Institutional Ownership

CUSIP: 50107A104

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

$0.87

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / Common Stock
Symbol
KRON
Price per share
$0.87
Price from insider filings
$0.87
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • KRON - Kronos Bio, Inc. - Common Stock is tracked under CUSIP 50107A104.
  • Latest finished 13F holder period is not available.
  • Schedule 13D/13G significant owner rows are not currently available.

What Changed

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • Reported value moved from $16,126 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 50107A104?
CUSIP 50107A104 identifies KRON - Kronos Bio, Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Institutional Holders of Kronos Bio, Inc. - Common Stock (KRON) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$16,126 $0.87 0
2025 Q3 16,128 $16,126 +$16,126 $1.00 1
2025 Q2 0 $0 -$15,790,182 $0.87 0
2025 Q1 19,132,784 $15,790,464 -$625,093 $0.82 47
2024 Q4 19,649,673 $18,665,523 -$792,903 $0.95 56
2024 Q3 19,704,103 $19,700,585 -$2,248,644 $1.00 52
2024 Q2 20,645,660 $25,556,191 -$1,590,484 $1.24 55
2024 Q1 21,700,397 $28,231,891 -$6,453,976 $1.30 57
2023 Q4 26,745,874 $33,427,928 -$4,595,965 $1.25 58
2023 Q3 30,266,227 $39,328,312 -$2,264,963 $1.30 63
2023 Q2 31,591,332 $54,317,965 -$1,182,464 $1.72 80
2023 Q1 32,396,272 $47,327,252 -$3,356,353 $1.46 86
2022 Q4 34,494,303 $55,877,865 -$2,972,560 $1.62 94
2022 Q3 36,074,689 $120,851,708 -$3,060,166 $3.35 90
2022 Q2 36,910,104 $134,378,804 -$21,147,007 $3.64 90
2022 Q1 38,994,222 $282,032,437 -$21,840,911 $7.23 91
2021 Q4 41,046,470 $557,830,415 +$1,058,701 $13.59 80
2021 Q3 35,955,919 $753,633,856 -$25,676,168 $20.96 80
2021 Q2 39,757,863 $952,008,187 +$87,935,702 $23.95 76
2021 Q1 33,255,601 $969,057,123 +$55,820,261 $29.27 69
2020 Q4 31,348,530 $928,520,047 +$915,228,048 $29.87 69
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .